EGFR mutations in non-small-cell lung cancer (#NSCLC) are twice as common among Asian patients compared to Caucasian patients, posing a significant management challenge. Two presentations at #ESMOAsia23 provide insights into recent treatment options. The subgroup analysis of Asian patients in the MARIPOSA-2 trial supports the main trial analysis showing a significant improvement in PFS with amivantamab plus chemotherapy compared to chemotherapy alone in patients progressing on osiemrinib. An exploratory analysis of the FLAURA2 trial suggested that the addition of platinum-based chemotherapy to first-line osimertinib did not impact acquired resistance mechanisms and should not influence targeted second-line treatment options. To learn more about this topic, and the challenges ahead in EGFR-mutated #NSCLC, read the # ESMODailyReporter article commented by Antonio Passaro 👉https://ow.ly/CR9B50QeLri
ESMO - European Society for Medical Oncology’s Post
More Relevant Posts
-
November was #lungcancerawarenessmonth, but months passing by shouldn't take away our motivation to find more effective and less toxic treatments for people affected by this condition. These are the first results of #AFM24 in NSCLC, and I feel incredibly proud to work with a team that has this "mantra" in mind (more effective but also less toxic), puts patients first, and wakes up every day willing to abate this disease. #innateimmunity #immunotherapy #oncology #clinicaltrials #clinicalresearch #NSCLC
Following our earlier promising #ASH23 update, we are also pleased to announce positive data for our innate cell engager (ICE®) #AFM24 in combination with the PD-L1 checkpoint inhibitor atezolizumab, in heavily pretreated EGFR-Wildtype Non-Small Cell Lung Cancer (#NSCLC) patients. We are encouraged by these promising results, especially considering that patients in this setting are often left without viable treatment options. We will be hosting a webcast today, December 11 at 1:30 p.m. PST / 4:30 p.m. EST / 10:30 PM CET, to discuss the data in more detail. You can read the full press release at: https://lnkd.in/dJXhGpdk
-
🎥 New Breakthroughs in Endometrial Cancer Treatment 🔬 We're excited to share key insights from SGO 2024 presented by Prof Jean-Francois Baurain (Cliniques Universitaires Saint-Luc) Discover groundbreaking results from the Duo-O study, where the addition of olaparib to durvalumab and carboplatin/paclitaxel/bevacizumab has shown promising improvements in PFS, especially in patients with homologous recombination deficiency. Additionally, delve into the first-in-human trial of raludotatug deruxtecan (R-DXd), a novel ADC targeting cadherin-6, which is achieving remarkable response rates in highly pretreated patients. Discover these updates.👇 For all ESGO & SGO 2024 videos, find the link in the comments! #MediMix #ESGO2024 #SGO2024 #GynaecologicalCancer #OncologyInnovation
-
🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗨 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 In our latest episode, Prof Emmanuel Seront and Prof Christof Vulsteke provide a detailed analysis of the KEYNOTE-B61 study, a significant leap forward in the treatment of non-clear cell renal cancer, as presented at ASCO. Discover how the combination of lenvatinib and pembrolizumab is setting new standards for patient care, showing promising results beyond its established success in endometrial and clear cell renal cancers. 👇 View all WND GU videos - link in the comments! #MediMix #GUCancer #RenalCancer #OncologyInnovation
-
🎖️Today we share the Editor's Choice #Article "Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI" 👏by John Wen-Cheng Chang et al. Chang Gung University 📌Link here: https://lnkd.in/d2PafZbs 🔆Editor comment: EGFR-TKIs are the standard treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC) patients. The authors retrospectively analyzed pretreatment clinical factors from records of 2190 patients and established a novel nomogram which can stratify EGFR mutation positive NSCLC patients undergoing 1G/2G TKI monotherapy into five different risk groups, which will provide additional information on the optimal therapeutic options for such patients🔆
-
-
Did you know? In addition to Jess Paulus' in-person poster presentation at 2024 ASCO® Annual Meeting, we also have three online publications. Be sure to check them out: 📌 Real-world clinical effectiveness and treatment patterns in the early-stage esophageal/gastroesophageal junction cancer (EC/GEJC) population treated in the community oncology setting in the United States 🔗 https://lnkd.in/gsykMtac 📌 Real-world (rw) treatment (tx) patterns and clinical outcomes in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC): Insights from The US Oncology Network electronic health record (EHR) 🔗 https://lnkd.in/grAiJBmP 📌 Pan-tumor circulating tumor DNA testing in the community oncology setting. 🔗 https://lnkd.in/gT_fmB82 #ASCO24 #CommunityOncology
-
November is #PancreaticCancerAwarenessMonth. Pancreatic cancer has very poor survival rates. Our scientists are dedicated to researching which genes🧬are involved in this type of cancer and find new approaches to treatment. Our work also aims to transform the landscape for patients with pancreatic cancer by making the most innovative new drugs available to patients as quickly as possible, and ensuring treatments are developed for those cancers that have yet to benefit significantly from modern advances in precision medicine. Learn more⬇️ https://lnkd.in/enhmHwwQ
-
-
Using systemic anti-cancer therapy (SACT) near end-of-life (EOL) is linked to negative outcomes, including increased hospitalization and costs. Despite recommendations to reduce chemotherapy within 14 days of death, national SACT rates in this period remain unchanged. Critics argue that EOL metrics might miss patients benefiting from aggressive treatment. In this #newresearch published in JAMA Oncology, researchers from Yale Cancer Center, MD Anderson Cancer Center, and Flatiron Health explore if “aggressive” SACT use near EOL improved outcomes in advanced/metastatic cancer patients. This research challenges common EOL oncology practices and emphasizes the need to understand economic factors shaping treatment decision in the evolving landscape of EOL oncology care. Visit our website to learn more: https://lnkd.in/e6ftweKk
-
March is #prostateancer awareness month and what better time to hear about the latest findings in prostate cancer therapies? We have some updates from the Phase II #BRCAAway trial (NCT03012321), demonstrating the benefits of #combinationtherapy over #sequentialtherapy. 🔦 At #ASCOGU 2024, we spoke with Kim Chi, MD, BC Cancer Vancouver Centre, who commented on findings from the Phase II #BRCAAwaytrial (NCT03012321) of #abiraterone with #olaparib, or either agent as #monotherapy in patients with metastatic castration resistant prostate cancer (#mCRPC). 🎥 Combining #abiraterone and #olaparib resulted in superior survival, which is consistent with results from the PROpel (NCT03732820), MAGNITUDE (NCT03748641) and TALAPRO-2 (NCT03395197) trials. 🌟 Despite the results favoring patients with #BRCA1/2 alterations, this trial demonstrated the benefits of combination therapy over sequential therapy. Learn more 👉 https://lnkd.in/eQhDKBy5 #Oncology #GUsm #PCsm #prostatecancerawarenessmonth #VJOncology
-
-
When combating colorectal cancer, maximising longevity is essential. Discover the latest treatments with Prof. Gerald Prager as he imparts late-stage options designed for long-term management of advanced CRC. Prof. Gerald Prager gives an overview of what HCPs should consider for achieving a long-term response in advanced colorectal cancer (CRC), including: > Understanding CRC therapy as a continuum of care > What to consider while making treatment selections. > What therapy alternatives are available for CRC patients, third-line and beyond? Tap into the future of care with us here: https://ow.ly/FXOU50QyJuJ #MedEd #FreeMedEd #MedicalEducation #Oncology #CRC
-
A great weekend read: Antiproliferative and Antitelomerase Effects of Silymarin on Human Colorectal and Hepatocellular Carcinoma Cells by Daruosh Rahimi et al. Read here: https://lnkd.in/eMN6mybq #PlantaMedica #LetsGrowTogether Image Description: Fig. 1 Silymarin inhibits the growth of human cancer cells. Human liver HepG2 (a) and colorectal (b) cancer cells were cultured overnight and treated with 0 to 150 μg/mL silymarin for 24–72 and 24 h, respectively. At the end of treatment, the cell growth was determined by the MTT assay. Silymarin treatments were compared to control cells (treated with DMSO vehicle alone) and represented themean of six independent experiments.
-
